The morbidity and mortality associated with diabetic complications impose a huge socioeconomic burden worldwide. Therefore, the ultimate goal of managing diabetes mellitus (DM) is to lower the risk of macrovascular complications and highly morbid microvascular complications such as diabetic nephropathy (DN) and diabetic retinopathy (DR). Potential benefits of incretin-based therapies such as glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors on the diabetic macrovascular complications have been recently suggested, owing to their pleiotropic effects on multiple organ systems. However, studies primarily investigating the role of these therapies in diabetic microvascular complications are rare. Nevertheless, preclinical and limited clinical data suggest the potential protective effect of incretin-based agents against DN and DR via their anti-inflammatory, antioxidative, and antiapoptotic properties. Evidence also suggests that these incretin-dependent and independent beneficial effects are not necessarily associated with the glucose-lowering properties of GLP-1 RAs and DPP-4 inhibitors. Hence, in this review, we revisit the preclinical and clinical evidence of incretin-based therapy for DR and DN, the two most common, morbid complications in individuals with DM. In addition, the review discusses a few recent studies raising concerns of aggravating DR with the use of incretin-based therapies.

Citations

Citations to this article as recorded by  

• Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice
  Andrew J. Barkmeier, Yihong Deng, Kavya Sindhu Swarna, Jeph Herrin, Eric C. Polley, Guillermo E. Umpierrez, Rodolfo J. Galindo, Joseph S. Ross, Mindy M. Mickelson, Rozalina G. McCoy
  Ophthalmology Retina.2026; 10(2): 142.     CrossRef
• Redox-Driven Blood–Nerve Barrier Dysfunction in Diabetic Peripheral Neuropathy: Mechanisms and Therapeutic Opportunities
  Wei-Hsiu Huang, Chih-Shung Wong
  Antioxidants.2026; 15(6): 670.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration
  Reut Shor, Andrew Mihalache, Atefeh Noori, Renana Shor, Radha P. Kohly, Marko M. Popovic, Rajeev H. Muni
  JAMA Ophthalmology.2025; 143(7): 587.     CrossRef
• Efficacy and Safety of the Utilization of Dipeptidyl Peptidase IV Inhibitors in Diabetic Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials
  Moeber Mahzari, Muhannad Alqirnas, Moustafa Alhamadh, Faisal Alrasheed, Abdulrahman Alhabeeb, Wedad Al Madani, Hussain Aldera
  Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1425.     CrossRef
• Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy
  Andrew J. Barkmeier, Jeph Herrin, Kavya Sindhu Swarna, Yihong Deng, Eric C. Polley, Guillermo E. Umpierrez, Rodolfo J. Galindo, Joseph S. Ross, Mindy M. Mickelson, Rozalina G. McCoy
  Ophthalmology Retina.2024; 8(10): 943.     CrossRef
• Incretin-based therapy: a new horizon in diabetes management
  Malek Zarei, Navideh Sahebi Vaighan, Mohammad Hadi Farjoo, Soosan Talebi, Mohammad Zarei
  Journal of Diabetes & Metabolic Disorders.2024; 23(2): 1665.     CrossRef
• Anti-Inflammatory Effects of GLP-1R Activation in the Retina
  Alessandra Puddu, Davide Maggi
  International Journal of Molecular Sciences.2022; 23(20): 12428.     CrossRef
• Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
  Anu Grover, Komal Sharma, Suresh Gautam, Srishti Gautam, Monica Gulati, Sachin Kumar Singh
  Current Diabetes Reviews.2021; 17(4): 397.     CrossRef
• SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
  Christopher El Mouhayyar, Ruba Riachy, Abir Bou Khalil, Asaad Eid, Sami Azar
  International Journal of Endocrinology.2020; 2020: 1.     CrossRef
• Novel therapeutic agents for the treatment of diabetic kidney disease
  Rachel E. Hartman, P.S.S. Rao, Mariann D. Churchwell, Susan J. Lewis
  Expert Opinion on Investigational Drugs.2020; 29(11): 1277.     CrossRef
• Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors
  Minyoung Lee, Jiyu Sun, Minkyung Han, Yongin Cho, Ji-Yeon Lee, Chung Mo Nam, Eun Seok Kang
  Diabetes Care.2019; 42(11): 2057.     CrossRef
• Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
  Jae Hyun Bae, Sunhee Kim, Eun-Gee Park, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
  Endocrinology and Metabolism.2019; 34(1): 80.     CrossRef
• Serum adipocytokines are associated with microalbuminuria in patients with type 1 diabetes and incipient chronic complications
  Tomislav Bulum, Marijana Vučić Lovrenčić, Martina Tomić, Sandra Vučković-Rebrina, Vinko Roso, Branko Kolarić, Vladimir Vuksan, Lea Duvnjak
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(1): 496.     CrossRef
• Protective Effects of Incretin Against Age-Related Diseases
  Di Zhang, Mingzhu Ma, Yueze Liu
  Current Drug Delivery.2019; 16(9): 793.     CrossRef
• Dipeptidyl Peptidase-4 Inhibitors and Inflammation: Dpp-4 Inhibitors Improve Mean Pleatelet Volume and Gamma Glutamyl Transferase Level
  Deniz Avcı
  Journal of Biosciences and Medicines.2019; 07(02): 42.     CrossRef
• The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin
  Annayya R. Aroor, Camila Manrique-Acevedo, Vincent G. DeMarco
  Cardiovascular Diabetology.2018;[Epub]     CrossRef

Diabetes is a common metabolic disorder with a worldwide prevalence of 8.3% and is the leading cause of visual loss, end-stage renal disease and amputation. Recently, genome-wide association studies (GWASs) have identified genetic risk factors for diabetic microvascular complications of retinopathy, nephropathy, and neuropathy. We summarized the recent findings of GWASs on diabetic microvascular complications and highlighted the challenges and our opinion on future directives. Five GWASs were conducted on diabetic retinopathy, nine on nephropathy, and one on neuropathic pain. The majority of recent GWASs were underpowered and heterogeneous in terms of study design, inclusion criteria and phenotype definition. Therefore, few reached the genome-wide significance threshold and the findings were inconsistent across the studies. Recent GWASs provided novel information on genetic risk factors and the possible pathophysiology of diabetic microvascular complications. However, further collaborative efforts to standardize phenotype definition and increase sample size are necessary for successful genetic studies on diabetic microvascular complications.

Citations

Citations to this article as recorded by  

• Genetic Determinants of Microvascular Complications of Type 1 Diabetes Mellitus: New Data from a Replication Study
  Bulat I. Yalaev, Rita I. Khusainova, Ildar R. Minniakhmetov, Dmitry D. Panteleev, Madina I. Yevloyeva, Minara S. Shamkhalova, Yulia Y. Golubkina, Ekaterina A. Dobreva, Marina V. Shestakova, Natalia G. Mokrysheva
  Biomedicines.2026; 14(6): 1199.     CrossRef
• A Cross-Sectional Comparative Study of Retinal Findings in Diabetic and Non-diabetic Chronic Kidney Disease Patients
  Sanjeet R Gandhi, Raghavendra Ijeri, Sandeep Patil
  Cureus.2025;[Epub]     CrossRef
• Genetics of diabetes
  Shiwali Goyal, Jyoti Rani, Mohd Akbar Bhat, Vanita Vanita
  World Journal of Diabetes.2023; 14(6): 656.     CrossRef
• Plasma thrombin-activatable fibrinolysis inhibitor and the 1040C/T polymorphism are risk factors for diabetic kidney disease in Chinese patients with type 2 diabetes
  Qinghua Huang, Dujin Feng, Lianlian Pan, Huan Wang, Yan Wu, Bin Zhong, Jianguang Gong, Huijun Lin, Xianming Fei
  PeerJ.2023; 11: e16352.     CrossRef
• The G Allele of the rs12050217 Polymorphism in the BDKRB1 Gene Is Associated with Protection for Diabetic Retinopathy
  Leticia A. Brondani, Daisy Crispim, Julia Pisco, Jorge A. Guimarães, Markus Berger
  Current Eye Research.2019; 44(9): 994.     CrossRef
• Genome‐wide association study identifies new susceptibility loci for diabetic nephropathy in Korean patients with type 2 diabetes mellitus
  Kyung H. Jeong, Jin S. Kim, Jeong‐Taek Woo, Sang Y. Rhee, Yu H. Lee, Yang G. Kim, Ju‐Young Moon, Su K. Kim, Sun W. Kang, Sang H. Lee, Yeong H. Kim
  Clinical Genetics.2019; 96(1): 35.     CrossRef
• Diabetic polyneuropathy, deep white matter lesions, and carotid atherosclerosis: is there any association?
  Sevgi Ferik, Hayat Güven, Mehlika Panpallı Ateş, Işık Conkbayır, Selçuk Çomoğlu, Bülent Güven
  Neurological Sciences.2018; 39(1): 103.     CrossRef
• Altered expression of WFS1 and NOTCH2 genes associated with diabetic nephropathy in T2DM patients
  Sahar A. Sharaf, Nagwa A. Kantoush, Dina F. Ayoub, Alshaymaa A. Ibrahim, Amaal A. Abdelaal, Rokaya Abdel Aziz, Mahmoud M. ElHefnawi, Amira N. Ahmed
  Diabetes Research and Clinical Practice.2018; 140: 304.     CrossRef
• Precision medicine in diabetes prevention, classification and management
  Fangying Xie, Juliana CN Chan, Ronald CW Ma
  Journal of Diabetes Investigation.2018; 9(5): 998.     CrossRef
• Clinical worthlessness of genetic prediction of common forms of diabetes mellitus and related chronic complications
  R. Buzzetti, S. Prudente, M. Copetti, M. Dauriz, S. Zampetti, M. Garofolo, G. Penno, V. Trischitta
  Nutrition, Metabolism and Cardiovascular Diseases.2017; 27(2): 99.     CrossRef
• Diabetic macular oedema: clinical risk factors and emerging genetic influences
  Ebony Liu, Jamie E Craig, Kathryn Burdon
  Clinical and Experimental Optometry.2017; 100(6): 569.     CrossRef
• Normoalbuminuric diabetic kidney disease
  Chao Chen, Chang Wang, Chun Hu, Yachun Han, Li Zhao, Xuejing Zhu, Li Xiao, Lin Sun
  Frontiers of Medicine.2017; 11(3): 310.     CrossRef
• Biomarkers of Diabetic Retinopathy
  Daniel Shu Wei Ting, Kara-Anne Tan, Val Phua, Gavin Siew Wei Tan, Chee Wai Wong, Tien Yin Wong
  Current Diabetes Reports.2016;[Epub]     CrossRef
• The (CTG)n repeat polymorphism in CNDP1 gene
  Kátia G. Santos
  Indian Journal of Medical Research.2016; 144(1): 6.     CrossRef
• Association Between Heme Oxygenase-1 Promoter Polymorphisms and the Development of Albuminuria in Type 2 Diabetes
  Eun Young Lee, Yong-ho Lee, Soo Hyun Kim, Kyu Sik Jung, Obin Kwon, Beom Seok Kim, Chung Mo Nam, Chun Sik Park, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Hyun Chul Lee
  Medicine.2015; 94(43): e1825.     CrossRef

Citations

Citations to this article as recorded by  

• A Case of Septo-Optic Dysplasia Resulting in Central Diabetes Insipidus and Nonobstructive Bilateral Hydronephrosis
  Jong Hyun Kim, Kwang Bok Lee, Jeonghun Lee, Soo Min Nam, Kang-Woo Lee, Eu Gene Hwang, Geon Gil
  Korean Journal of Medicine.2014; 87(2): 209.     CrossRef